Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
Inspira (NASDAQ: IINN) entered a non-binding term sheet on Jan 5, 2026 for an all-share acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment based on a $180 million pre-money valuation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inspira (NASDAQ: IINN) entered a non-binding term sheet on Jan 5, 2026 for an all-share acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment based on a $180 million pre-money valuation. The Company expects to sign Definitive Agreements within ~four weeks, subject to shareholder approval and customary closing conditions.
The plan allocates $12 million of proceeds to existing respiratory and blood-monitoring technology development, proposes contingent value rights to protect current shareholders, and aims for FDA 510(k) clearance for the platform previously validated across dozens of patient samples.
Positive
- $15 million strategic equity investment at closing
- Pre-money valuation of $180 million
- Plans to allocate $12 million to existing technologies
- Targeting FDA 510(k) clearance for the liquid biopsy platform
- Clinical validation across dozens of patient samples
Negative
- Term sheet is non-binding; definitive agreements not executed
- Transaction subject to shareholder approval and customary conditions
- Strategic investor identity not yet disclosed
- Closing expected after ~four weeks, creating timing uncertainty
Details
News Market Reaction – IINN
On Jan 5, the day this news came out, IINN closed 7.76% above the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Strategic equity investment
- $15 million
- Concurrent investment proposed in term sheet
- Pre-money valuation
- $180 million
- Valuation framework for proposed investment
- Allocated to existing tech
- $12 million
- Portion of investment for respiratory and blood monitoring
- Liquid biopsy market size
- $58 billion
- Projected global market over coming decade
- Purchase orders
- $49.5 million
- Binding purchase orders reaffirmed Dec 2025
- Registered direct offering
- $1.8 million
- Gross proceeds from Dec 2025 offering
- SEPA capacity
- $25 million
- Standby Equity Purchase Agreement size
- Shelf registration size
- $75,000,000
- Form F-3 shelf filed Nov 25, 2025
Historical Context
-
Reaffirmed $49.5M purchase orders with revenue recognition from 2026.
-
Registered direct offering and $25M SEPA to fund operations.
-
Japan patent for Convertible Dual Lumen Cannula valid through 2041.
-
Expanded blood lab capabilities and larger facility for diagnostics.
-
Completed HYLA blood sensor study with 95%–99% reported accuracy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
liquid biopsy medical
circulating tumor cells medical
ai-powered cellular analysis technical
510(k) regulatory pathway regulatory
contingent value rights financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholders of Inspira relating to its existing technologies
RA'ANANA, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has entered into a non-binding term sheet (the “Term Sheet”), outlining the principal terms of a proposed two-part transaction that would include the acquisition of an advanced liquid biopsy diagnostics business, together with a concurrent
Dagi Ben-Noon, Chief Executive Officer of Inspira, commented “We are positioning the Company to expand into a high-growth diagnostics market through the planned acquisition of a development-ready liquid biopsy platform, supported by a clear regulatory pathway, alongside a significant strategic equity investment of
Equity Investment
The proposed transaction includes a
The identity of the Strategic Investor is expected to be disclosed following shareholder approval and execution of the Definitive Agreements. As part of the transaction structure, Inspira intends to allocate
Strategic Acquisition
As part of the proposed transaction, Inspira would acquire an advanced liquid biopsy diagnostics business in an all-share acquisition. The acquisition would enable Inspira to enter the rapidly growing liquid biopsy market through a proprietary platform (the “Platform”) designed to isolate and characterize circulating tumor cells from standard blood samples. The Platform incorporates AI-powered cellular analysis intended to support cancer characterization and treatment decision-making. In clinical validation studies conducted to date across dozens of patient samples, the Platform has demonstrated a high level of concordance with traditional tissue biopsy, highlighting its potential to provide clinically meaningful insights that may complement existing diagnostic approaches.
The Platform’s initial clinical focus is breast cancer, with potential applicability across additional oncology indications. The global liquid biopsy market is projected to reach a market size of approximately
Following the acquisition, the Company expects to pursue U.S. Food and Drug Administration (“FDA”) clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging established regulatory precedents. Importantly, an existing reimbursement code is already in place for the intended clinical use, providing a clear path to reimbursement upon regulatory clearance.
Shareholder Protection Framework
The proposed transaction would include a dedicated shareholder protection framework designed to preserve the full economic upside of Inspira’s existing respiratory and blood-monitoring platforms for current shareholders, while simultaneously enabling participation in the growth potential of the liquid biopsy platform. Under this framework, Inspira’s shareholders of record at the completion of the Definitive Agreements are expected to receive contingent value rights, ensuring that any future realization of value from Inspira’s respiratory technology assets is allocated exclusively to the existing shareholders. This structure is intended to allow Inspira to expand into a new diagnostics growth platform without diluting the economic interests of its current shareholders in the Company’s established respiratory and blood monitoring technologies.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential execution of the Definitive Agreements, the timing thereof and the need for shareholder approval for the proposed acquisition, the potential for the closing of the equity financing, the Company’s expansion into a high-growth diagnostics market through the planned acquisition of a development-ready liquid biopsy platform the anticipated valuation of the Company, the potential benefits and advantages of strategic acquisition and establishment of a dual-platform medical technology business, the anticipated timeline for the regulatory approval of the acquired liquid biopsy technology, the expected pursuit of FDA clearance for the biopsy platform through the 510(k) regulatory pathway, the expected use of proceeds from the equity investment, the shareholder protection framework and the expected issuance of contingent value rights and the Company’s future operations and strategic positioning following completion of the transaction. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
1 https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.